What Happens When Your Reviewer Misinterprets a Foreign Article?

Pharmacovigilance (PV) thrives on accuracy. Every signal, every adverse event, and every piece of literature feeds into a bigger picture: the safety profile of a drug and, ultimately, patient safety. But what happens when the very foundation of this work—a published article in a medical journal—is misinterpreted by the reviewer?

The risks are amplified when the article in question is written in a foreign language. Misinterpretation in this context can have far-reaching consequences: incorrect coding of adverse events, missed safety signals, flawed regulatory reporting, and reputational damage for pharmaceutical companies.

This blog dives into what really happens when foreign articles are misunderstood in pharmacovigilance, why it occurs, its potential impact, and how solutions like Tesserblu can help organizations safeguard the quality and reliability of their literature review process.

Why Literature Review Is Critical in Pharmacovigilance

Pharmacovigilance teams monitor global medical literature to detect and assess adverse events (AEs) associated with medicinal products. Literature sources are essential for:

• Identifying new or rare adverse drug reactions (ADRs).

• Understanding patient-reported outcomes.

• Assessing benefit-risk profiles.

• Meeting regulatory requirements such as those outlined by EMA (European Medicines Agency) and FDA.

The International Society of Pharmacovigilance (ISoP) and ICH guidelines emphasize literature monitoring as a mandatory safety surveillance activity. Hence, the accuracy of interpretation cannot be compromised.

The Challenge: Foreign Language Literature in PV

With science being global, crucial safety-related information is often published in local journals in German, French, Japanese, Spanish, Mandarin, or other regional languages. These journals may contain case reports, clinical trial outcomes, or observational studies relevant to PV.

For multinational companies, ignoring these publications isn’t an option. Regulators expect comprehensive literature coverage. That means reviewers must work with multilingual content—either relying on translation tools or in-house language experts.

Here lies the problem:

1. Language Nuances – Medical terminology doesn’t always translate cleanly. Words may have subtle connotations that a machine translator misses.

2. Cultural Context – Clinical practices and reporting styles vary across regions, leading to misinterpretation if unfamiliar.

3. Idiomatic Usage – A phrase that seems like a symptom may actually be describing patient background or unrelated observations.

4. Ambiguity in Translation – Automatic tools may generate awkward or incorrect phrases, confusing the reviewer.

   
   

What Happens When Misinterpretation Occurs?

Let’s break down the potential consequences of misinterpreting a foreign-language article in PV:

1. Incorrect Case Identification

A reviewer might wrongly assume that a reported adverse event is linked to a drug of interest when it’s not—or fail to recognize a true case.

• Example: A Spanish article describes “dolor abdominal leve” (mild abdominal pain) as a symptom unrelated to medication, but the reviewer interprets it as a drug-related AE.

  
  

2. Missed Safety Signals

If a reviewer underestimates or overlooks an adverse reaction due to translation errors, the company may miss an emerging signal.

• Example: A Japanese study notes “皮膚発疹” (skin rash) linked to a new therapy. If mistranslated as “skin condition” without attribution, the signal is lost.

  
  

3. Inaccurate MedDRA Coding

PV professionals rely on MedDRA (Medical Dictionary for Regulatory Activities) coding to standardize AEs. Misinterpretation may lead to incorrect coding.

• Example: A French article mentions “vertige” (dizziness), but a reviewer codes it as “vertigo” (a more severe clinical entity).

  
  

4. Regulatory Non-Compliance

Regulators like EMA require comprehensive and accurate reporting of literature findings. Submitting flawed ICSRs (Individual Case Safety Reports) based on misinterpretation can lead to compliance issues, audits, or penalties.

5. Wasted Resources

Time spent chasing false positives or re-reviewing mistranslated articles slows down workflow and drains resources.

6. Reputation Risks

Pharma companies risk credibility with regulators, partners, and even patients if errors from misinterpretations surface.

Why Reviewers Misinterpret Foreign Articles

Even highly trained reviewers can fall into traps when handling non-English literature. Some key reasons include:

1. Over-reliance on Machine Translation – Tools like Google Translate are fast but not always medically accurate.

2. Limited Language Expertise – Reviewers may not have domain fluency in the article’s original language.

3. Time Pressure – PV teams work under tight reporting timelines, increasing the likelihood of superficial reviews.

4. Ambiguous Article Structure – Some journals use case descriptions embedded in narrative text, making interpretation harder.

5. Lack of Specialized Tools – Without proper technology, reviewers juggle PDFs, translation windows, and coding references manually.

   
   

Real-World Implications

To understand the gravity, consider two hypothetical but realistic scenarios:

• Scenario A: Over-Reporting A German journal case study mentions “Kopfschmerzen während der Schwangerschaft” (headaches during pregnancy) in a patient taking a vitamin supplement. The reviewer mistakenly interprets this as an ADR linked to the drug, generating an unnecessary ICSR. The regulatory team spends weeks clarifying, wasting time and resources.

  
  

• Scenario B: Under-Reporting A French oncology journal documents “thrombopénie sévère” (severe thrombocytopenia) following a novel immunotherapy. Due to mistranslation, the reviewer considers it a baseline condition rather than an AE, failing to report a potentially life-threatening event.

Both scenarios show that errors cut both ways—overreporting and underreporting—and both compromise pharmacovigilance quality.

How to Prevent Misinterpretation

Organizations can adopt several measures:

1. Hire Multilingual Reviewers – While effective, it’s expensive and not always feasible.

2. Use Professional Medical Translators – Ensures accuracy but adds time and cost.

3. Develop Reviewer Training Programs – Enhances awareness of linguistic pitfalls.

4. Leverage Technology – Advanced tools can reduce dependency on manual translation.

This is where Tesserblu can make a real difference.

How Tesserblu Helps

Tesserblu is designed to transform how pharmacovigilance teams handle literature review, especially when dealing with foreign-language content. By combining advanced natural language processing (NLP), AI-driven translation, and pharmacovigilance-specific context awareness, it minimizes misinterpretation risks.

Here’s how:

1. Domain-Specific Translation Engine

Unlike generic translation tools, Tesserblu is tuned for medical and pharmacovigilance contexts. Terms like “rash,” “reaction,” “event,” or “case report” are interpreted with clinical accuracy.

2. Automated Article Parsing

Tesserblu extracts relevant sections—such as adverse event mentions, drug associations, and patient demographics—so reviewers don’t waste time wading through unrelated content.

3. Integrated MedDRA Coding Support

The system maps identified adverse events directly to MedDRA terms, reducing errors from manual interpretation.

4. AI-Powered Context Understanding

It distinguishes between background conditions and drug-related events, helping prevent false positives. For example, it knows when “diabetes” is a patient history vs. a suspected ADR.

5. Multilingual Coverage

Tesserblu supports major global languages relevant to pharmacovigilance literature, ensuring teams don’t miss critical signals published outside English journals.

6. Audit-Ready Reports

Every interpretation step is documented, giving regulators confidence in the transparency and reliability of your literature monitoring process.

The Strategic Advantage

Adopting Tesserblu not only reduces misinterpretation risks but also:

• Improves efficiency by cutting manual review time.

• Enhances compliance with global regulatory requirements.

• Allows teams to focus on signal evaluation rather than struggling with translations.

• Reduces the need for expensive multilingual staff.

Ultimately, it ensures that patient safety decisions are based on accurate, high-quality data.

Conclusion

In pharmacovigilance, the integrity of literature review cannot be left to chance. Misinterpreting a foreign article isn’t just a clerical error—it has real consequences for drug safety, regulatory compliance, and company credibility.

While human expertise will always be central to PV, tools like Tesserblu offer a powerful safeguard, ensuring that reviewers can accurately process foreign literature without missing—or fabricating—critical safety signals.

By combining domain-specific AI with regulatory alignment, Tesserblu helps PV teams move beyond language barriers, protect patients, and uphold the highest standards of pharmacovigilance. Book a meeting if you are interested to discuss more.